Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people

BACKGROUND: There is uncertainty about the associations of angiotensive enzyme (ACE) inhibitor and angiotensin receptor blocker (ARB) drugs with COVID-19 disease. We studied whether patients prescribed these drugs had altered risks of contracting severe COVID-19 disease and receiving associated inte...

Descripción completa

Detalles Bibliográficos
Autores principales: Hippisley-Cox, Julia, Young, Duncan, Coupland, Carol, Channon, Keith M, Tan, Pui San, Harrison, David A, Rowan, Kathryn, Aveyard, Paul, Pavord, Ian D, Watkinson, Peter J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Special Populations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509391/
https://www.ncbi.nlm.nih.gov/pubmed/32737124
http://dx.doi.org/10.1136/heartjnl-2020-317393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509391/
https://www.ncbi.nlm.nih.gov/pubmed/32737124
http://dx.doi.org/10.1136/heartjnl-2020-317393

Ejemplares similares